ChoA Pharmaceutical Co.Ltd (034940) - Total Assets
Based on the latest financial reports, ChoA Pharmaceutical Co.Ltd (034940) holds total assets worth ₩63.04 Billion KRW (≈ $42.72 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of ChoA Pharmaceutical Co.Ltd to assess how comfortably operating cash covers total debt obligations.
ChoA Pharmaceutical Co.Ltd - Total Assets Trend (2001–2025)
This chart illustrates how ChoA Pharmaceutical Co.Ltd's total assets have evolved over time, based on quarterly financial data. See 034940 net assets for net asset value and shareholders' equity analysis.
ChoA Pharmaceutical Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
ChoA Pharmaceutical Co.Ltd's total assets of ₩63.04 Billion consist of 54.2% current assets and 45.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 3.6% |
| Accounts Receivable | ₩17.81 Billion | 27.5% |
| Inventory | ₩11.72 Billion | 18.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩549.56 Million | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how ChoA Pharmaceutical Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 034940 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChoA Pharmaceutical Co.Ltd's current assets represent 54.2% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, up from 3.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 27.5% of total assets.
ChoA Pharmaceutical Co.Ltd Competitors by Total Assets
Key competitors of ChoA Pharmaceutical Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
ChoA Pharmaceutical Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.08 | 1.05 | 2.28 |
| Quick Ratio | 0.73 | 0.68 | 1.77 |
| Cash Ratio | 0.00 | 0.00 | 0.25 |
| Working Capital | ₩2.76 Billion | ₩1.75 Billion | ₩27.34 Billion |
ChoA Pharmaceutical Co.Ltd - Advanced Valuation Insights
This section examines the relationship between ChoA Pharmaceutical Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -9.3% |
| Total Assets | ₩64.68 Billion |
| Market Capitalization | $11.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values ChoA Pharmaceutical Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ChoA Pharmaceutical Co.Ltd's assets decreased by 9.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ChoA Pharmaceutical Co.Ltd (2001–2025)
The table below shows the annual total assets of ChoA Pharmaceutical Co.Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩64.68 Billion ≈ $43.83 Million |
-9.31% |
| 2024-12-31 | ₩71.32 Billion ≈ $48.33 Million |
-3.91% |
| 2023-12-31 | ₩74.22 Billion ≈ $50.30 Million |
-13.33% |
| 2022-12-31 | ₩85.64 Billion ≈ $58.04 Million |
+6.37% |
| 2021-12-31 | ₩80.51 Billion ≈ $54.56 Million |
-2.26% |
| 2020-12-31 | ₩82.38 Billion ≈ $55.83 Million |
-5.03% |
| 2019-12-31 | ₩86.74 Billion ≈ $58.78 Million |
+3.21% |
| 2018-12-31 | ₩84.04 Billion ≈ $56.95 Million |
+0.63% |
| 2017-12-31 | ₩83.52 Billion ≈ $56.60 Million |
+11.21% |
| 2016-12-31 | ₩75.10 Billion ≈ $50.89 Million |
+1.01% |
| 2015-12-31 | ₩74.35 Billion ≈ $50.38 Million |
+0.41% |
| 2014-12-31 | ₩74.05 Billion ≈ $50.18 Million |
+4.56% |
| 2013-12-31 | ₩70.82 Billion ≈ $47.99 Million |
+31.86% |
| 2005-12-31 | ₩53.70 Billion ≈ $36.39 Million |
+42.36% |
| 2004-12-31 | ₩37.72 Billion ≈ $25.56 Million |
-23.63% |
| 2003-12-31 | ₩49.39 Billion ≈ $33.47 Million |
-18.49% |
| 2002-12-31 | ₩60.60 Billion ≈ $41.07 Million |
-17.59% |
| 2001-12-31 | ₩73.54 Billion ≈ $49.83 Million |
-- |
About ChoA Pharmaceutical Co.Ltd
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral ne… Read more